All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
GSK and Flagship to jointly fund up to $150 million upfront
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
